[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"British Columbia Cancer Agency\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":669},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,46,74,97,124,153,190,220,242,269,294,321,343,375,396,415,437,468,504,526,553,572,602,624,642],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100304716","partial-prostate-salvage-high-dose-rate-brachytherapy-100304716",false,"NCT03246802","Partial Prostate Salvage High Dose Rate Brachytherapy","High Dose Rate Partial Prostate Brachytherapy as Salvage Treatment for Local Failures After Previous External Beam Radiotherapy","SalvageHDR","Inclusion Criteria:\n\n* Age \\>45 and Life expectancy \\>10 years\n* Previous External Beam Radiotherapy (EBRT) or LDR brachytherapy w\n* \\> 3 year interval since EBRT or LDR Brachytherapy\n* No late toxicity from prior EBRT ≥ grade 2\n* PSA \\> nadir + 2 ng\u002Fml and \\\u003C 10 ng\u002Fml\n* PSA Doubling time \\> 6 months\n* Radiographic evidence corresponding with site of recurrence in an under-dosed or untreated site. The recurrence should correspond to the site of original disease or be located in the seminal vesical +\u002F- adjacent prostate as only area of recurrence (i.e. unifocal recurrence).\n* Per Investigator, recurrence is suitable for implant with HDR brachytherapy and patient is suitable for procedure under anesthesia, spinal or general.\n* Negative staging of the abdomen\u002Fpelvis and bones.\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* Not compliant with criteria above\n* Unable to give informed consent","MALE","45 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","A dose-response relationship for radiation in the management of prostate cancer is well established. Local recurrence of prostate cancer after external beam radiotherapy occurs in at least 40% of patients treated because of inability to deliver sufficient dose through external beam techniques. These patients respond well to re-irradiation using brachytherapy with about 50% of selected patients remaining free of recurrence 5 years after salvage. Advanced imaging using multiparametric Magnetic Resonance Imaging (mpMRI) allows identification of the site of recurrence, permitting partial prostate salvage brachytherapy. There is extensive literature on Low Dose Rate salvage brachytherapy but less on High Dose Rate.",[28],"Recurrent Prostate Cancer",[30,31,32],"recurrent prostate cancer","mpMRI","salvage HDR brachytherapy","RECRUITING","2026-06-24",{"date":36,"type":37},"2026-06-29","ACTUAL",{"date":39,"type":37},"2018-01-01",{"date":41,"type":22},"2037-01-01",{"name":43,"class":44},"British Columbia Cancer Agency","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100580317","phase-2-phase-ii-randomized-trial-of-2-versus-5-fraction-prostate-stereotactic-ablative-radiotherapy-for-intermediate-risk-prostate-cancer-100580317","NCT06835725","Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer","PHASE II RANDOMIZED TRIAL OF 2- VS 5-FRACTION PROSTATE STEREOTACTIC ABLATIVE RADIOTHERAPY","ADAPT-25","Inclusion Criteria:\n\n* • Age 18 or older.\n\n  * Able to provide informed consent.\n  * ECOG performance status 0 - 2.\n  * Fit for all protocol treatment and follow-up.\n  * Life Expectancy \\> 5 years.\n  * Histologically confirmed adenocarcinoma of the prostate, NCCN low or intermediate risk, with biopsy performed within the last 18 months:\n\nLow risk = cT1-T2a,Gleason ≤ 6, and PSA \\\u003C 10ng\u002FmL. Intermediate risk = at least one of: cT2b\u002FT2c, PSA 10-20ng\u002FmL, or Gleason 7, but not high risk.\n\n* 6 months of Androgen Deprivation Therapy (ADT) is permitted for those with NCCN unfavorable intermediate risk disease (aka high-tier intermediate risk disease), defined as intermediate risk disease with one or more of: two or three intermediate risk features, Gleason 4+3, or ≥50% biopsy cores positive.\n* For those with NCCN unfavorable intermediate risk disease, it is permitted for ADT to have been initiated prior to study enrollment provided it is possible for radiotherapy to be completed before completion of 6 months of ADT.\n* Prostate volume \\\u003C100cc based on imaging or digital rectal examination.\n* PSA within 90 days prior to registration. If ADT is started before registration, then the PSA must have been done no more than 90 day prior to the date of the first ADT injection.\n* CT abdomen and pelvis within the 6 months prior to registration (may be omitted for NCCN low risk participants). If particpant started on ADT prior to registration, CT should be done before first ADT injection.\n* Bone scan within the 6 months prior to of registration (may be omitted for NCCN low risk participants). If particpant started on ADT prior to registration, bone scan should be done before first ADT injection.\n* Must be appropriate for and willing to undergo implantation of prostate fiducial markers and Space OAR Hydrogel.\n\nExclusion Criteria:\n\nClinical stage cT3 or greater. Gleason score 8 or greater. PSA \\> 20ng\u002FmL or greater. NCCN high or very high risk. Pelvic nodal metastases. Distant metastases. Previous malignancy within the last 5 years except basal or squamous cell carcinomas of the skin.\n\nPrevious pelvic radiotherapy. Any prior active local treatment for prostate cancer. Participants previously on active surveillance are eligible if they continue to meet all other eligibility criteria.\n\nUnilateral or Bilateral hip prostheses. Medical conditions likely to make radiotherapy inadvisable (e.g., inflammatory bowel disease).\n\nMedical condition that would make implantation of fiducial markers or hydrogel rectal spacer unsafe, in the opinion of the treating physician (e.g., pelvic or prostate abscess).\n\nMedical condition or implant that prohibits MRI (e.g. pacemaker) Trans-urethral resection of the prostate (TURP), GreenLight Laser or Holmium Laser Prostate procedure within 6 months of radiotherapy.","18 Years",{"count":56,"type":22},100,[58],"PHASE2","Prostate cancer is a common cancer, and a significant cause of cancer death in men. There are many potentially curative treatment options for prostate cancers that have not spread. A relatively recent option is called prostate stereotactic ablative radiotherapy (SABR). SABR is a form of external beam radiotherapy, where patients receive a small number (5-7) of treatments (also called fractions) of radiation delivered in a highly accurate and precise fashion. Standard prostate SABR is generally given in 5 fractions and has been shown to be at least as effective as conventional external beam radiotherapy. Disease control with SABR appears excellent, and it compares favorably to surgery in terms of side effects and quality of life.\n\nIn theory, reducing the number of fractions from 5 to 2 may improve disease control and reduce side effects, in addition to providing added convenience for patients. Small studies suggest prostate SABR in 2 fractions may be highly effective and well tolerated. However, there is little available data comparing 2 and 5 fraction SABR head to head to tell us which is superior.\n\nTwo fraction SABR involves delivery of 2 large dose fractions of radiotherapy which could result in significant side effects if proper precautions are not taken. The use of continuous tracking of the prostate gland position during treatment delivery reduces the risk of missing the prostate or overdosing organs near by. Such tracking has been shown to reduce bladder side effects. Also, the use of a rectal spacer placed between the prostate and rectum has been shown to reduce bowel side effects. Also, advanced artificial intelligence (AI)-directed computer applications could potentially improve the targeting of radiation during each treatment.\n\nThe ADAPT-2 study is a randomized phase II trial comparing standard 5-fraction SABR with an experimental 2-fraction approach in men with intermediate risk prostate cancer. All treatment, whether 5 or 2-fractions, will use continuous prostate tracking (also called triggered imaging) and a rectal spacer (called Space OAR Hydrogel) to minimize side effects. The trial will also evaluate the potential of a new AI-guided dose guidance application to see if it can improve current methods of targeting SABR each day. This aspect of the study will be offline; that is, the AI application will not be used to actually target treatment for the trial patients. Rather, daily targeting of SABR will use standard conventional means, and the AI application will be studied in a simulated fashion to determine it is useful and can be incorporated into workflow.\n\nThe main goal of the ADAPT-25 study is to compare the long-term side effects and quality of life between 5- and 2-fraction prostate SABR. Secondary goals will be to compare the long-term disease control between 5-and 2-fraction prostate SABR, and to evaluate whether a novel AI-directed dose guidance application can be used to better target SABR by reducing doses to neighboring organs, and whether it can be easily fit into prostate SABR workflow.",[61],"Prostate CA",[63,64,65],"stereotactic radiotherapy","SBRT","SABR","2026-06-22",{"date":34,"type":37},{"date":69,"type":37},"2025-09-04",{"date":71,"type":22},"2033-04-30",{"name":43,"class":44},2,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":81,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":45},"100584156","single-vs-hypofractionated-irradiation-for-timely-access-to-partial-breast-radiotherapy-100584156","NCT06885671","Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy","Phase II Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy: SHIFT-PB","Inclusion Criteria:\n\n* Female participants age 40 or older\n* Able to provide informed consent\n* pTis-2 pN0 cM0 breast cancer, with tumor size \\\u003C3 cm as per provincial guidelines\n* Able to complete electronic or paper entry of participant reported outcomes independently or with assistance from caregiver\u002Ffamily\u002Ffriend\u002Fresearch staff\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2\n* A history and physical (clinical breast) examination, including ECOG performance status, performed within 8 weeks prior to enrollment.\n* Participant is judged able to:\n\n  * Maintain a stable position during therapy\n  * Tolerate immobilization device(s) that may be required to deliver PBI safely\n* Negative pregnancy test for People of Child-Bearing Potential (POCBP) within 4 weeks of RT start date\n\nExclusion Criteria:\n\n* History of non-breast malignancies except adequately treated non-melanoma skin cancers, in situ cancers treated by local excision or other cancers curatively treated with no evidence of disease for ≥ 5 years.\n* Uncontrolled concurrent malignant cancer\n* Seroma not visible\n* Ipsilateral implanted cardiac device\n* Prior radiotherapy requiring summation for planning.\n* Requirement for a radiation boost (as determined by the treating investigator)\n* Positive surgical margins\n* Surgical cavities lacking clear delineation (surgical clips are not required but may assist in target delineation)\n* Known germline BRCA1\u002F2 mutation.\n* Serious medical comorbidities precluding radiotherapy (e.g., connective tissue disorders such as lupus or scleroderma)\n* Pregnant or breastfeeding","FEMALE","40 Years",{"count":84,"type":22},60,[25],"Partial Breast Irradiation (PBI) is a targeted radiation approach commonly administered post-lumpectomy, specifically targeting the tumour bed. This targeted therapy reduces the exposure to other nearby tissues such as lungs, heart, and chest wall. However, traditional PBI treatment involves lengthy multiple fraction courses which presents a burden to patients from rural and remote communities, who must travel long distances to receive high quality cancer care. The purpose of this study is to compare single fraction (SF) PBI vs. multiple fraction (MF) PBI.",[88],"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","2026-06-18",{"date":91,"type":37},"2026-06-23",{"date":93,"type":22},"2026-06-08",{"date":95,"type":22},"2029-12-31",{"name":43,"class":44},{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":45},"100638922","a-comparison-of-68gadotatate-and-18fambf3tate-for-the-staging-and-assessment-of-neuroendocrine-malignancies-100638922","NCT07621146","A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies","A Prospective and Head-to-head Comparison of [68Ga] Ga-DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies: NET-COMPARE Study","NET-COMPARE","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients referred for and meeting institutional criteria for a \\[68Ga\\]DOTATATE PET\u002FCT for the investigation of a known or suspected neuroendocrine malignancy (BC Cancer criteria APPENDIX A).\n\nExclusion Criteria:\n\n* Pregnant and breast-feeding patients.\n* Patients unwilling or unable to undergo a second PET\u002FCT.\n* Patients exceeding the safe weight limit of the scanner (204.5 kg) or who cannot fit through the PET\u002FCT bore (70cm diameter).","ALL",{"count":107,"type":22},51,"OBSERVATIONAL","Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin receptors (SSTR) which requires specific PET scan tracers to sufficiently capture on images. The current standard of care tracer at BC Cancer for SSTRs on NETs is 68Ga-DOTATATE. This project seeks to identify if 18F-AmBF3-TATE (a tracer that has established safety from phase 1 trial results), is comparable in disease detection, no. of lesions identified, image quality, safety and overall accuracy, to 68Ga-DOTATATE.",[111,112,113,114],"Neuroendocrine Tumors, NET","Pheochromocytoma\u002FParaganglioma","SSTR-expressing Tumors","Medullary Thyroid Carcinoma","NOT_YET_RECRUITING","2026-05-27",{"date":118,"type":37},"2026-06-02",{"date":120,"type":22},"2026-09-15",{"date":122,"type":22},"2028-03",{"name":43,"class":44},{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},"100409352","550020-vs-sabr-or-brachytherapy-for-primary-oligometastatic-prostate-cancer-treatment-prompt-100409352","NCT04610372","5500\u002F20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)","Moderate Versus Ultra Hypofractionation or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment","PROMPT","Inclusion Criteria:\n\n* Signed study specific informed consent\n* European Cooperative Oncology Group performance status 0 to 2\n* Histologically confirmed adenocarcinoma of the prostate\n* Any Tumor stage, any T, any N, M1\n* No prior therapy for prostate cancer apart from androgen deprivation\n* Planned for long-term androgen deprivation therapy (greater than 9 months in duration)\n* Patient is able and willing to complete the quality of life questionnaires, and other assessments that are a part of this study\n* For brachytherapy arms, patient must be technically suitable for brachytherapy according to investigator, in terms of bladder function and prostate size.\n\nExclusion Criteria:\n\n* High metastatic burden defined as 5 or more bone metastases or visceral metastases\n* Contraindications to EBRT such as active inflammatory bowel disease or previous pelvic radiation\n* For Brachytherapy Arms =: Any prior Transurethral resection of prostate",{"count":133,"type":22},168,[25],"We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate in patients with oligometastatic prostate cancer. Secondary aims include assessment of progression-free survival (PFS) and overall survival (OS) as well as cost-effectiveness. We hypothesize that ultrahypofractionation will maintain favorable toxicity profiles and quality of life while achieving comparable or better efficacy, thereby providing a convenient and cost-effective alternative to moderately hypofractionated EBRT.",[137],"Oligometastatic Prostate Cancer",[139,140,141,142,143],"prostate adenocarcinoma","oligometastases","radiotherapy","hypofractionation","brachytherapy","2026-04-30",{"date":146,"type":37},"2026-05-06",{"date":148,"type":37},"2021-07-12",{"date":150,"type":22},"2033-06-30",{"name":43,"class":44},4,{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":105,"minAge":160,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":165,"conditions":166,"keywords":175,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":189},"100532125","phase-1-clic-2201-for-the-treatment-of-relapsedrefractory-b-cell-malignancies-100532125","NCT06208735","CLIC-2201 for the Treatment of Relapsed\u002FRefractory B Cell Malignancies","CLIC-02: A Phase I Trial of CLIC-2201 for the Treatment of Relapsed\u002FRefractory B Cell Malignancies","Inclusion Criteria in Cohort A:\n\nParticipants must meet the following criteria to be enrolled on the trial:\n\n1. Participants in the cohort A must be 18 years of age or older of age at time of informed consent.\n2. Participants must provide written informed consent.\n3. Participants must have a relapsed or refractory B cell lymphoma, including one of the following:\n\n   1. diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS),\n   2. high grade B cell lymphoma NOS,\n   3. high grade B cell lymphoma with MYC and BCL2 and\u002For BCL6 rearrangements,\n   4. primary mediastinal large B-cell lymphoma (PMBCL),\n   5. aggressive B cell lymphoma transformed from an indolent lymphoma,\n   6. mantle cell lymphoma (MCL),\n4. Participants must have refractory or relapsed disease, defined as one of the following:\n\n   1. Relapse or refractory disease after at least 2 lines of therapy, OR\n   2. Any relapse after autologous or allogeneic hematopoietic cell transplantation (HCT), OR\n   3. Any relapse after CAR-T cell therapy.\n5. Participants must have adequate organ function at enrolment, defined as:\n\n   1. Left ventricular ejection fraction (LVEF) ≥40%,\n   2. Creatinine clearance using Cockcroft-Gault of \\> 30 mL\u002Fmin, AND\n   3. ALP\u002FALT \\\u003C 5X upper limit of normal (ULN), conjugated bilirubin \\\u003C 2X ULN, and no evidence or history of liver cirrhosis.\n6. Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 or Karnofsky Score ≥50%.\n7. Females of child-bearing potential and sexually active males must agree to use a highly effective contraception method (see section 5.4) through to at least one year following administration of the CLIC-2201 product.\n8. Participants with accessible disease, must be willing to undergo a tumour biopsy at enrolment. For participants with a recent (within 3 months) tumor biopsy, access to the archival biopsy is acceptable.\n\nInclusion Criteria in Cohort B:\n\n1. Participants in the cohort B must be between 1-39 years of age at the time of consent.\n2. For participants who are under the age of consent as defined by REB requirements, parent or legal guardian of the participant must provide the informed consent and the participant's assent\u002Fconsent must be obtained (if applicable).\n3. Participants must have a relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL).\n4. Participants must have refractory or relapsed disease, defined as one of the following:\n\n   1. Relapse or refractory disease after at least 2 lines of therapy, OR\n   2. Any relapse after autologous or allogeneic hematopoietic cell transplantation (HCT), OR\n   3. Any relapse after CAR-T cell therapy.\n5. Participants in cohort B and\u002For those who have received CD22 targeted therapy must have documentation of CD22 tumour expression within the 6 months prior to study screening, and after any prior CD22 directed therapy (if applicable).\n6. Participants must have adequate organ function at enrolment, defined as:\n\n   1. Left ventricular ejection fraction (LVEF) ≥45%,\n   2. Creatinine clearance using Cockcroft-Gault or Schwartz equation of \\> 30 mL\u002Fmin, AND\n   3. ALP\u002FALT \\\u003C 5X upper limit of normal (ULN), conjugated bilirubin \\\u003C 2X ULN, and no evidence or history of liver cirrhosis.\n7. Participants must have a Karnofsky or Lansky Score ≥50%.\n8. Participants of reproductive age must agree to use a highly effective contraception method (see section 5.4) through to at least one year following administration of the CLIC-2201 product.\n9. Participants must be willing to undergo a bone marrow biopsy at enrolment.\n\nExclusion Criteria:\n\n1. Any uncontrolled or serious active infection at the time of enrolment.\n2. Active autoimmune disease requiring immunosuppressive therapy within 4 weeks of enrolment.\n3. Live vaccine ≤6 weeks prior to enrolment\n4. Active Graft Versus Host Disease (GVHD) requiring systemic immunosuppressive therapy within 4 weeks of enrolment.\n5. Diagnosis of primary central nervous system lymphoma (PCNSL)\n6. Treatment with any of the following in the specified time period before leukapheresis:\n\n   1. Allogeneic HCT within 3 months,\n   2. Autologous HCT within 3 months,\n   3. CD19 CAR-T cell infusion within 3 months,\n   4. Donor lymphocyte infusion (DLI) within 3 months,\n   5. Bendamustine within the last 6 months,\n   6. Any investigational agent within 30 days or 5 half-lives (whichever is shorter),\n   7. Systemic administration of therapeutic dose corticosteroids (\\>20 mg\u002Fday prednisone or equivalent for adults and ≥ 12 mg\u002Fm2\u002Fday for paediatric participants) within 7 days prior to leukapheresis.\n   8. Immunosuppressive therapies (i.e., calcineurin inhibitors, methotrexate, mycophenolate, rapamycin) within 4 weeks, unless used as treatment for the B cell malignancy.\n   9. Oral chemotherapy agents (i.e., venetoclax) within 5 half-lives. An exception to this is that bruton tyrosine kinase (BTK) inhibitors like ibrutinib can be continued in participants with mantle cell lymphoma throughout the trial period.\n7. Other concurrent malignancy or a prior malignancy treated within the past 2 years, except carcinoma in situ of the skin or cervix treated with curative intent and with no evidence of active disease.\n8. Concomitant genetic syndrome associated with bone marrow failure such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure or immunodeficiency syndrome.\n9. Active (confirmed by PCR) hepatitis B or hepatitis C at time of screening confirmed by PCR.\n10. Any Human Immunodeficiency Virus (HIV) infection at time of screening.\n11. Hypersensitivity to fludarabine or cyclophosphamide.\n12. Any allergy to gentamycin or its derivatives\n13. Participants who do not meet the minimum weight requirement for the planned dose level.\n14. Pregnant or nursing participants.","1 Year",{"count":162,"type":22},24,[164],"PHASE1","This is a phase I dose-finding trial of an autologous CD22 targeting chimeric antigen receptor (CAR)-T cell product, called CLIC-2201, for participants with relapsed\u002Frefractory B cell malignancies. In the proposed trial, eligible enrolled participants will undergo leukapheresis for autologous T cell collection to enable CLIC-2201 manufacturing, followed by lymphodepletion with cyclophosphamide and fludarabine, then intravenous infusion of the autologous CLIC-2201 product. The trial will use the 3+3 design to escalate or de-escalate the dose level of CLIC-2201 administered. Participants will be monitored for safety and tolerability up to day 365 following CLIC-2201 infusion.\n\nThe primary objective is to evaluate the safety and tolerability of CLIC-2201 and estimate the maximum tolerated dose (MTD) of CLIC-2201 in B-cell malignancies.\n\nThe secondary objectives are to evaluate the (i) feasibility; (ii) anti-tumour activity of CLIC-2201; (iii) and characterize the pharmacokinetic (PK) profile of CLIC-2201.\n\nExploratory objectives will include: i) characterizing the cellular and humoral immune responses against CLIC-2201 up to 1 year following infusion of CLIC-2201; (ii) characterizing the phenotype and gene expression profile of CLIC-2201 cells; (iii) evaluating immune and tumour cells at baseline and relapse for biomarkers of response or toxicity; (iv) evaluating serum cytokines, circulating tumour DNA (ctDNA) and B cell aplasia as biomarkers of clinical outcomes; and (v) assessing the quality of life.",[167,168,169,170,171,172,173,174],"B-Cell Leukemia","Non-Hodgkin's Lymphoma","B-cell Acute Lymphoblastic Leukemia","Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Mantle Cell Lymphoma","B-cell Lymphoma",[176,177,178,179,180],"Chimeric Antigen Receptor T cells","CLIC-2201","CD22","Immunotherapy","CAR-T cell","2026-03-30",{"date":183,"type":37},"2026-04-03",{"date":185,"type":37},"2025-01-02",{"date":187,"type":22},"2027-08-01",{"name":43,"class":44},7,{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":105,"minAge":197,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":206,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":45},"100615635","help-study---towards-high-throughput-and-efficient-long-axial-pet-with-oral-18ffdg-100615635","NCT07295171","HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG","HELP","Inclusion Criteria:\n\n* Age ≥19 years\n* Participants who have received a standard of care \\[18F\\]FDG PET\u002FCT and are willing to undergo a study specific oral \\[18F\\]FDG PET\u002FCT within 2 weeks.\n\nExclusion Criteria:\n\nParticipant Inclusion Criteria\n\n* Age ≥19 years\n* Participants who have received a standard of care \\[18F\\]FDG PET\u002FCT and are willing to undergo a study specific oral \\[18F\\]FDG PET\u002FCT within 2 weeks.\n\nParticipant Exclusion Criteria\n\n* Pregnant or breast-feeding\n* Medically unstable (e.g., acute illness, unstable vital signs)\n* Urinary incontinence\u002Fcatheter.\n* Immobile, frail or vulnerable patients who cannot leave the department and would require an uptake room in any case.\n* Patients whose fasting blood sugar at the SOC PET was \\>11.0 mmol\u002Fl\n* Unable to swallow.\n* Patients with nasogastric tubes, percutaneous gastrostomy or other non-anatomical routes for nutrition.\n* Unable to lie flat for 1h (subset of participants - first 5 participants only).\n* Claustrophobia requiring medication.\n* Undergoing active treatment or assessment of an upper digestive tract tumor (stomach\u002Fesophagus)\n* Unable to provide written consent\n* Patients receiving biguanide anti-hyperglycemic agents (e.g. Metformin).\n* Insulin dependent diabetics.","19 Years",{"count":199,"type":22},27,[25],"Typically, PET scans involve an IV injection of 18F-FDG that helps identify cancer. Patients are scanned 60 minutes after injecting 18F-FDG. This study aims to assess the feasibility of a different method of administration - oral ingestion (rather than IV) of 18F-FDG through delayed imaging to identify the optimal time for scanning after consuming the drug. The study will aim to recruit 15-24 individuals who will receive two PET scans - one using delayed oral 18F-FDG imaging and a second regular 18F-FDG. The analysis will focus on establishing a suitable protocol for this administration route while considering patient preference and image quality.",[203,204,205],"Multiple Cancers","Multiple Indications Cancer","Feasibility Studies",[207,208,209,210,211],"Oral FDG","LAFOV","Long-axial Field-of-view Scanner","Quadra","Low-dose Oral Radiopharmaceuticals","2026-03-26",{"date":214,"type":37},"2026-03-31",{"date":216,"type":37},"2026-02-18",{"date":218,"type":22},"2027-02-18",{"name":43,"class":44},{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":81,"minAge":54,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":45},"100483576","stratification-of-vulvar-squamous-cell-carcinoma-by-hpv-and-p53-status-to-guide-excision-100483576","NCT05576831","STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision","STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision: STRIVE Study","STRIVE","Inclusion Criteria:\n\n* Histologically confirmed primary diagnosis of vulvar squamous cell carcinoma\n* Surgically staged FIGO (International Federation of Gynaecology and Obstetrics) I-II disease\n* Margin status after primary surgery:\n\n  * HPV-I VSCC: margins are negative for cancer but \\\u003C8mm, and\u002For positive for dVIN, and\u002For positive for p53 abnormality on IHC\n  * HPV-A VSCC: margins are negative for cancer but \\\u003C8mm (regardless of in-situ (HSIL) margin status)\n* Age ≥18 years old\n* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate. A similar process must be followed for sites outside of Canada as per their respective cooperative group's procedures.\n\nExclusion Criteria:\n\n* Recurrent vulvar squamous cell carcinoma\n* Non-squamous cell carcinoma histotypes\n* FIGO stage III- IV disease\n* Patients referred for adjuvant radiation for close margins\n* Margins positive for cancer",{"count":229,"type":22},249,[25],"Vulvar cancer affects the external genitalia of women. This type of cancer is uncommon, arising mostly in older women and has been neglected in research and clinical trials. Over the recent years, investigators have learned that the most common type of vulvar cancer; vulvar squamous cell carcinoma (VSCC) develops from pre-cancerous lesions via different pathways. One pathway is associated with human papillomavirus (HPV) infection, and another is related to chronic inflammatory skin conditions (and not HPV). The VSCCs arising from these two principal pathways; HPV- associated (HPV A) and HPV-independent (HPV I), behave differently with different risks of recurrence, and different response to treatments. HPV-I VSCC are further defined by mutations in TP53 (Tumor Protein 53), which identify a group of patients with aggressive disease. Currently treatment is the same for all women with vulvar cancer, and consequently many women may be overtreated, and many women are not treated enough. Given evolving knowledge of this disease, this 'one size fits all' approach may no longer be appropriate. The investigators aim in this study is to see if personalizing surgical therapy for patients with vulvar cancer based on HPV and TP53 status will improve outcomes.",[233],"Vulvar Cancer","2026-01-31",{"date":236,"type":37},"2026-02-03",{"date":238,"type":37},"2024-11-25",{"date":240,"type":22},"2031-11-25",{"name":43,"class":44},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":45},"100531528","multi-omic-approach-to-study-hdr-brachytherapy-for-favorable-risk-and-low-tier-intermediate-risk-prostate-cancer-100531528","NCT06200974","Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer","Multi-omic Approach to Study High Dose Rate (HDR) Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer","BrachyTRACKS","Inclusion Criteria:\n\n* Favorable risk and intermediate-risk prostate cancer with estimated life expectancy of at least 10 years.\n* Clinical stage T1c-T2b, PSA \\\u003C 20, Gleason \\\u003C 8\n* ECOG 0-1\n* Low tier intermediate-risk prostate cancer is defined by: a single NCCN intermediate risk factor (either Gleason 7(3+4) and PSA \\\u003C 10 ng\u002Fml OR Gleason 6 and PSA 10-20 ng\u002Fml)\n* Extensive favorable-risk disease is defined as: clinical stage T1c-T2a, PSA \\\u003C 10, Gleason 6, ≥ 50% of biopsy cores containing cancer, PSA density \\> 0.2 ng\u002Fcc,\n* Selected intermediate risk patients not defined above\n\n  * T1c\u002FT2a\n  * PSA \\\u003C 10 and Gleason 4+3\n  * PSA \\> 10 (\\\u003C 20) and Gleason 3+4\n  * PSA 10-15 ng\u002Fml and Gleason 4+3 and \\\u003C 33% cores involved\n  * Max tumor length in any core 10 mm\n* No androgen deprivation therapy (ADT)\n* Signed study specific informed consent.\n\nExclusion Criteria:\n\n* Prior radical surgery for carcinoma of the prostate,\n* Prior pelvic radiation\n* Prior chemotherapy for prostate cancer,\n* Claustrophobic or unable to undergo MRI\n* Patients unsuitable for general anesthesia, on blood thinners which cannot be stopped for 24 hours, or who have contraindications to radiotherapy such as systemic sclerosis, or inflammatory bowel disease",{"count":56,"type":22},"This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy. This study takes a multi-omics approach to study the mechanism of action of HDR brachytherapy through metabolomics, immunological, transcriptomics, and spectroscopic profiling. The results of this study will clarify the optimal dose for HDR prostate brachytherapy by documenting the dose-response relationship seen in the changing tumor metabolites after HDR brachytherapy and investigate the immunogenicity of HDR brachytherapy.",[253],"Localized Prostate Carcinoma",[255,256,257,258,259,260],"Brachytherapy","TRACKS","High Dose Rate","Prostate cancer","favorable risk","intermediate risk","2026-01-29",{"date":263,"type":37},"2026-02-02",{"date":265,"type":37},"2024-02-01",{"date":267,"type":22},"2038-02-01",{"name":43,"class":44},{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":279,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":45},"100560244","using-tumour-dna-and-proteins-to-better-understand-how-pancreatic-cancer-responds-to-treatment-100560244","NCT06574620","Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment","Accelerating the Actionability of Treatment in Resected and Locally Advanced Pancreatic Cancer","ACCELERATE","Inclusion Criteria:\n\nParticipants must meet all of the following criteria prior to Pre-Baseline registration:\n\n1. Age 18 years or older.\n2. Histological or radiological diagnosis of resectable, borderline resectable, or locally advanced PDAC.\n3. Medically fit and planned to undergo laparoscopic procedure as part of standard of care.\n4. Able to give informed consent for the study-related procedures performed during laparoscopy.\n\nParticipants must meet all of the following criteria to be eligible for enrollment in the Main Study:\n\n1. Age 18 years or older.\n2. Enrolled in the Personalized Oncogenomics (POG) Program at BC Cancer.\n3. Histological and\u002For radiological diagnosis of resectable, borderline resectable, or locally advanced PDAC. Participants without a histological diagnosis of PDAC must undergo confirmatory histological diagnosis prior to treatment start date.\n4. Medically fit to undergo surgical resection of the primary lesion(s) as judged by the investigator (Resectable and Borderline Resectable Cohorts only).\n5. Planned for adjuvant (Resectable and Borderline Resectable Cohorts) or first-line (Locally Advanced Cohort) therapy with FOLFIRINOX or a gemcitabine-based regimen, either as part of routine care or in combination with an investigational agent(s) within another clinical trial. Participants may have received pre-operative therapy.\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n7. Adequate organ function as defined by the following laboratory results obtained within 28 days prior to enrollment date:\n\n   1. Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002FL.\n   2. Hemoglobin ≥ 9 g\u002FdL.\n   3. Platelets ≥ 75 x 10\\^9\u002FL.\n   4. Prothrombin time test and international normalized ratio (PT\u002FINR) and partial thromboplastin time (PTT) ≤ 1.5 x Upper Limit of Normal (ULN).\n   5. Total bilirubin ≤ 1.5 x ULN. Isolated bilirubin \\> 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \\\u003C 35%.\n   6. Aspartate aminotransferase (AST) and alanine aminotransferase (AST) ≤ 1.5 x ULN. If liver metastases are present, AST and ALT ≤ 5 x ULN is permitted.\n   7. Albumin ≥ 25 g\u002FL.\n   8. One of the following:\n\n      * Creatinine ≤ 1.5 x ULN.\n      * Calculated creatinine clearance (as calculated by Cockcroft-Gault formula) ≥ 40 mL\u002Fmin.\n      * 24-hour urine creatinine clearance ≥ 40 mL\u002Fmin.\n8. Life expectancy greater than 90 days as judged by the investigator.\n9. Able to give informed consent for the study procedures defined in this protocol.\n10. Measurable disease by RECIST 1.1. For those in the Resectable and Borderline Resectable Cohorts, measurable disease must be present prior to resection surgery.\n\nExclusion Criteria:\n\n1. Presence of distant or lymph node metastases. Individuals with metastatic PDAC are not eligible.\n2. Currently receiving adjuvant (Resectable and Borderline Resectable Cohorts) or systemic (Locally Advanced Cohort) anti-cancer therapy (chemotherapy or any other anti-cancer agent) with one exception: pre-operative therapy is permitted.\n3. Not fit for chemotherapy as judged by the investigator.\n4. Presence of brain metastases.\n5. Positive pregnancy test.\n6. Unable to comply with the study assessments and procedures defined in this protocol.\n7. Individuals who are otherwise judged by the investigator to be unfit to proceed with this protocol.",{"count":278,"type":22},200,[25],"The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are:\n\n* Is it feasible to obtain genetic test results within a timeframe that can help inform treatment decisions for individuals with PDAC?\n* Can the genetic test results provide information about how a tumour will respond to or resist treatment?\n\nParticipants will:\n\n* Receive standard chemotherapy to treat their cancer.\n* Provide samples of their blood, tissue, and fluid for genetic testing.\n* Visit the clinic every 4 weeks for check-ups and tests.\n* Complete questionnaires every 12 weeks.",[282,283,284,285],"Pancreatic Ductal Adenocarcinoma","Resectable Pancreatic Ductal Adenocarcinoma","Borderline Resectable Pancreatic Ductal Adenocarcinoma","Locally Advanced Pancreatic Ductal Adenocarcinoma","2026-01-15",{"date":288,"type":37},"2026-01-16",{"date":290,"type":37},"2025-11-28",{"date":292,"type":22},"2031-12",{"name":43,"class":44},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":105,"minAge":197,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":304,"conditions":305,"keywords":309,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":45},"100586713","stereotactic-radiotherapy-versus-palliative-conventional-radiotherapy-for-oligoprogressive-metastatic-cancers-100586713","NCT06918951","Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers","Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers: A Double-Blind Randomized Phase III Trial","Inclusion Criteria:\n\n1. Age 19 or older\n2. Able to provide informed consent\n3. Histologically confirmed solid malignancy (excluding lymphoma or myeloma) with metastatic disease detected on imaging\n4. Biopsy of metastasis at some time prior to enrollment is preferred, but not required\n5. ECOG performance status 0-2\n6. Life expectancy ≥ 6 months\n7. Progression meeting RECIST criteria in up to 5 individual lesions. Progression may be defined as:\n\n   1. Progression of an individual metastasis according to RECIST 1.1 criteria (≥ 20% enlargement of the tumour vs. baseline or nadir, taking as reference the smallest diameter seen prior to starting or during systemic therapy, and associated with a 5 mm minimum increase in size) OR\n   2. Unambiguous development of a new metastatic lesion at least 5 mm in size OR\n   3. Progressive enlargement of a known metastasis on 2 consecutive imaging studies 2-3 months apart with a minimum 5 mm increase in size from baseline.\n   4. A progressing primary tumor is eligible as per the criteria above\n8. If the participant is on systemic therapy at the time of oligoprogression:\n\n   The most recent systemic therapy agent must have been delivered for a total of at least 3 months, with an initial partial response (PR), complete response (CR) or stable disease (SD) prior to the development of oligoprogressive lesions\n9. If the participant is not on systemic therapy at the time of oligoprogression:\n\n   (i.e., \"oligorecurrence\"(1), however, included as \"oligoprogression\" for the purpose of this study protocol):\n10. There must be PR, CR or SD persisting for at least 3 months prior to the development of oligoprogressive lesions\n11. Participants who are not on systemic therapy at the time of oligoprogression must have other site(s) of disease (metastases or primary tumor) that are stable or resolved and have not received definitive treatment (inclusive of surgery, radical doses of radiotherapy including SABR, or ablation) and are not going to receive SABR.\n12. All sites of oligoprogression can be safely treated\n13. Restaging completed within 12 weeks prior to randomization (see section 5.1)\n14. Negative urine pregnancy test for People of Child-Bearing Potential (POCBP) within 4 weeks of radiotherapy start date.\n\nExclusion Criteria:\n\n1. Serious medical comorbidities precluding radiotherapy. These include ataxia-telangiectasia or scleroderma, Crohn's disease in participants where the gastrointestinal (GI) tract will receive radiotherapy, or ulcerative colitis where the bowel will receive radiotherapy.\n\n   a. For participants with oligoprogressive lesions in the lung or thorax, this includes interstitial lung disease.\n2. Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, provided that the composite plan meets dose constraints herein. For participants treated with radiation previously, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed in Appendix 1. A tissue recovery factor may be used in these calculations and if so, must be clearly documented, along with elapsed time from previous radiotherapy, and approved by the local principal investigator.\n3. Current malignant pleural effusion, malignant ascites, or leptomeningeal disease\n4. Inability to treat all sites of oligoprogressive disease\n5. Liver metastases requiring placement of fiducial markers for SABR, as this would compromise successful blinding. Liver metastases are eligible if: 1) they are treated at an institution that offers liver SABR without fiducial markers or 2) pre-existing markers such as surgical clips or calcifications would serve as fiducial markers\n6. Brain metastasis \\> 3.5 cm in size or a total volume of brain metastases greater than 30 cc.\n7. Clinical or radiologic evidence of spinal cord compression. Participants can be eligible if surgical resection has been performed.\n8. Participants with spine instability as judged by a Spinal Instability Neoplastic Score (SINS) of \\>12.\n9. Dominant brain metastasis requiring surgical decompression\n10. For participants with liver metastases; moderate\u002Fsevere liver dysfunction (Child Pugh B or C)\n11. Liver metastases located in the \"Biliary no fly zone\" defined for this trial as common biliary track, cystic duct and distal branches (1 cm) + 5 mm\n12. Surgical resection of all oligoprogression metastases (i.e. no lesion available to be treated with SABR)\n13. Pregnant or lactating individuals",{"count":302,"type":22},194,[25],"STOP-2 is a phase III multi-institutional double-blind randomized trial. 194 participants will be enrolled in this trial. Participants will be randomized in a 1:1 ratio between the Control Arm vs. the Experimental Arm.\n\nParticipants, enrolling oncologists, and the statistician will be blinded to trial arm assignment.\n\nIn the control arm, radiotherapy will consist of 8 Gy in 1 fraction to all sites of oligoprogression, and the experimental arm will consist of SABR treatment to all sites of oligoprogression.\n\nPrimary Objectives\n\n* To assess the impact of SABR, compared to palliative conventional radiotherapy, on Progression-free survival on next line systemic therapy (PFS-NEST), oncologic outcomes, and Quality of Life (QOL) in participants with 1-5 oligoprogressing lesions.\n* To assess the feasibility of the clinical trial in terms of accrual and success of double-blinding.\n\nSecondary Objectives\n\n* To evaluate and compare the impact of SABR and palliative radiation therapy on the overall survival (OS), progression free survival (PFS), polymetastatic progression-free survival (PPFS);\n* To assess and compare the proportion of participants receiving additional radiation therapy and other metastasis-directed interventions during follow-up between both arms;\n* To compare the impact of SABR and palliative radiation therapy on the time to initiation of the next line of systemic therapy;\n* To identify and compare the anatomic sites of disease progression between the experimental (SABR) and control (palliative radiation) arms;\n* To compare the treatment related toxicity among participants in each arm;\n* To evaluate and compare the quality of life among participants in each arm;\n* To assess the cost-effectiveness of the experimental arm compared to the control arm.",[306,307,308],"Oligoprogression","Oligometastatic Disease","OligoProgressive Metastatic Disease",[65,310,311,312],"Radiotherapy","Quality of life","Metastatic Cancer","2025-12-08",{"date":315,"type":37},"2025-12-15",{"date":317,"type":37},"2025-12-04",{"date":319,"type":22},"2033-06-01",{"name":43,"class":44},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":23,"phases":330,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":45},"100615383","high-dose-radiotherapy-for-palliation-hi-d-100615383","NCT07291895","High Dose Radiotherapy for Palliation (Hi-D)","A Prospective Single-blinded Randomized Study of High Dose Radiotherapy for Palliation: Hi-D","Inclusion Criteria:\n\n* Subjects must meet all the following criteria to be eligible for participation in this study:\n* Age 18 or older.\n* Able to provide informed consent\n* Patient has histologically confirmed solid tumour malignancy\n* ECOG performance status 0 - 2\n* Life Expectancy \\> 6 months\n* 1-5 target lesions larger than 5cm\n* A history and physical exam, including ECOG performance status, performed within 6 weeks prior to trial enrollment\n* Not suitable for or declined curative-intent treatment\n* Subject has had a CT neck, chest, abdomen and pelvis or PET-CT within 8 weeks prior to enrollment, and with 12 weeks of treatment\n* MRI spine for patients receiving RT to vertebral or paraspinal metastases\n* Patient is judged able to:\n\n  * Maintain a stable position during therapy\n  * Tolerate immobilization device(s) that may be required to deliver radiation safely\n\nExclusion Criteria:\n\n* \\- Hematologic malignancy.\n* Disease limited to intracranial sites\n* Serious medical co-morbidities precluding radiotherapy\n* Bone metastases with no soft tissue component\n* Prior radiation to target lesion that precludes delivery of repeat radiation. All such cases should be discussed with the local and study PIs.\n* Pregnant women",{"count":329,"type":22},20,[25],"The goal of this clinical trial is to evaluate the feasibility of single-blind randomization between two palliative regimens - standard 24 Gray in 3 fractions vs a high-dose (Hi-D) 27 Gray in 3 fractions with dose escalation within the tumor in participants with bulky metastatic cancer.\n\nThe main question",[333,334],"Metastases","Palliative Radiotherapy","2025-12-05",{"date":337,"type":37},"2025-12-18",{"date":339,"type":22},"2026-01-01",{"date":341,"type":22},"2029-08-31",{"name":43,"class":44},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":23,"phases":353,"briefSummary":354,"conditions":355,"keywords":358,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":45},"100612547","using-strength-tests-to-better-understand-how-pancreatic-cancer-affects-muscle-mass-and-quality-of-life-100612547","NCT07255001","Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life","Monitoring Physical Function Changes in Patients With Pancreatic Ductal Adenocarcinoma: Potential for Better Understanding of Treatment Trajectory and Survival","PanFit","Inclusion Criteria:\n\n* Age 18 years or older.\n* Histological and\u002For radiological diagnosis of resectable, non-resectable, or metastatic PDAC. For resectable PDAC, adjuvant setting only.\n* ECOG performance status 0-2.\n* Life expectancy greater than 6 months as judged by the investigator.\n* Planned for treatment, either as part of routine care or in combination with an investigational agent within another study.\n* Ability to hold a dynamometer with one hand.\n\nExclusion Criteria:\n\n* Individuals with CT imaging performed outside of Vancouver, BC, Canada.\n* Individuals who are unfit to undergo CT imaging of the third lumbar vertebra (L3).\n* Individuals who are currently participating in a structured moderate intensity resistance training program.\n* Individuals who are otherwise judged by the investigator to be unfit to proceed with this protocol.\n* Unable to comply with study assessments and follow-up.",{"count":352,"type":22},50,[25],"The goal of this clinical trial is to measure hand grip strength in adults with pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are:\n\n* Is it feasible to measure hand grip strength as part of a clinic visit?\n* Are changes in hand grip strength related to changes in body composition?\n* Is hand grip strength related to a person's well-being?\n* Is hand grip strength related to how a tumour responds to treatment?\n\nParticipants will squeeze a device with their hand to measure their hand grip strength and complete questionnaires about their well-being when they are seen in clinic for their regular medical care for PDAC.",[356,357],"Pancreatic Ductal Adenocarcinoma (PDAC)","Hand Grip Strength",[359,360,361,362,363,364,365,366,367],"Pancreatic ductal adenocarcinoma (PDAC)","Hand grip strength (HGS)","Quality of Life (QOL)","Body composition","Cachexia","Sarcopenia","Physical function","Skeletal muscle","Adipose tissue","2025-11-25",{"date":290,"type":37},{"date":371,"type":22},"2025-12",{"date":373,"type":22},"2027-12-31",{"name":43,"class":44},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":45},"100609145","radiotherapy-12gy-in-6-fractions-for-orbital-lymphoma-100609145","NCT07210749","Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma","A Phase II Trial Assessing 12 Gy in 6 Fractions Radiotherapy for Low-Grade B-cell Orbital Lymphoma","Inclusion Criteria:\n\n* Age ≥18 years with stage I-IV indolent NHL\\*\n* Able to provide informed consent\n* Histologically confirmed indolent NHL involving one or both orbits. If bilateral, biopsy of only one orbit is permitted as long as high clinical suspicion of contralateral orbit involvement\n* Measurable orbital disease after biopsy, either clinically or radiographically\n* ECOG performance status 0-3\n* Life expectancy \\>12 months\n* Available for treatment and follow-up (including scheduled post-treatment imaging and ophthalmologic exam)\n* Able and willing to complete quality of life questionnaires via paper or online portal if they provide their email address on the informed consent document\n\n  * Stage II-IV allowed but if systemic therapy given after RT the timing will be recorded, and subjects will be stratified according to receipt of systemic therapy\n\nExclusion Criteria:\n\n* Aggressive NHL histology (including grade 3B follicular lymphoma)\n* Prior RT to orbit\n* Patients requiring treatments outside standard clinical hours\n* Systemic therapy for lymphoma is not permitted within the period of time between 2 weeks prior to RT start and 2 weeks after RT completion\n* Patients who are pregnant\n* History of other malignancy within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death and\u002For treated with expected curative outcome (for example, appropriately treated non-melanoma skin cancer, carcinoma in-situ of the cervix, localized prostate cancer, breast ductal carcinoma in-situ, or stage I endometrial cancer)\n* Any medical condition that, in the investigator's judgement, would preclude the individual's safe participation in and completion of the study, or could affect interpretation of the results (e.g. pre-existing retinopathy, active connective tissue disease)\n* Inability to comply with study and follow-up procedures",{"count":383,"type":22},36,[25],"Current standard RT doses (24-25Gy) provide excellent disease control for patients with indolent B-cell orbital lymphoma, but can cause significant late toxicities. Ultra-low dose RT (4Gy in 2 fractions) has minimal toxicity but lower disease control, requiring intensive follow-up to salvage persistent tumors. Some centers are moving towards this dose as the new standard. A recent study using 12Gy in 4 fractions to any body site showed early data suggesting high disease control rates with minimal toxicity. This study assesses 12Gy in 6 fractions, aiming to enhance disease control over 4Gy while reducing toxicity compared to 24Gy.",[387],"Orbital Lymphoma","2025-10-02",{"date":390,"type":37},"2025-10-07",{"date":392,"type":22},"2025-11-01",{"date":394,"type":22},"2036-08-31",{"name":43,"class":44},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":23,"phases":403,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":45},"100534752","evidence-development-in-cancer-treatment---real-world-predictrw-100534752","NCT06242912","Evidence Development in Cancer Treatment - Real World: PREDiCTrw","Inclusion Criteria:\n\n* Subjects with cancer for which there remains ongoing questions regarding clinical effectiveness and\u002For cost effectiveness regarding a therapeutic agent\n* Eastern Co-operative Group (ECOG) 0-2\n* Life expectancy of at least 12 weeks\n* Adequate hematologic and end organ function for drug treatment per the clinician's assessment\n* Asymptomatic or treated brain metastases permitted\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than 1% per year during the treatment period and for at least 5 months after the last dose.\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse with a female partner of childbearing potential or who is pregnant) or use contraceptive measures, and agreement to refrain from donating sperm, during the treatment period and for at least 5 months after the last dose.\n* Ability to give informed consent for the study procedures defined in this protocol.\n\nExclusion Criteria:\n\n* Treatment with any approved or investigational agent or participation in another clinical trial with therapeutic intent within 14 days prior to enrollment.\n* Inability to complete quality of life questionnaires\n* Pregnancy or breastfeeding.\n* Any significant cardiovascular disease, comorbidity (i.e. recent major infection, HIV, tuberculosis) or major surgical procedure within 21 days that in the opinion of the investigator renders the proposed treatment unsafe.\n* Subjects who are otherwise felt by the treating clinician to be unfit to proceed with this protocol.",{"count":56,"type":22},[25],"This pilot clinical trial aims to assess the real world quality of life and survival of patients treated with therapy that has preliminary evidence of efficacy but uncertainty of the magnitude of clinical benefit or cost effectiveness in subjects with cancer. The goal of this study is to collect real world evidence with respect to quality of life and outcomes to support decision making.",[406],"Cancer","2025-09-22",{"date":409,"type":37},"2025-09-25",{"date":411,"type":37},"2024-01-22",{"date":413,"type":22},"2029-01",{"name":43,"class":44},{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":23,"phases":423,"briefSummary":424,"conditions":425,"keywords":426,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":431,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":45},"100424991","precision-oncology-evidence-development-in-cancer-treatment---clinical-predictc-100424991","NCT04814095","PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc","PREDiCTc","Inclusion Criteria:\n\n* Subject age greater than or equal to 18 years at the time of signature of informed consent.\n* Subjects with an incurable malignancy who have been identified to have a rare cancer or rare molecular aberration who is currently receiving Health Canada approved targeted therapy that is not nationally funded\n* ECOG 0-2\n* Life expectancy of at least 12 weeks\n* Adequate hematologic and end organ function for drug treatment per the clinician's assessment\n* Asymptomatic or treated brain metastases permitted\n* Ability to give informed consent for the study procedures defined in this protocol.\n\nExclusion Criteria:\n\n* Treatment with any approved or investigational agent or participation in another clinical trial with therapeutic intent within 14 days prior to enrollment.\n* Inability to complete quality of life questionnaires\n* Subjects who are felt by the treating clinician to be unfit to proceed with this protocol.",{"count":21,"type":22},[25],"This pilot clinical trial aims to assess the real world quality of life and survival of patients treated with targeted therapy that has preliminary evidence of efficacy in subjects with advanced rare cancers or cancer harbouring rare molecular aberrations. The treatment has been granted conditional or full approved by Health Canada (HC) as effective and safe. Due to the rarity of the cancer or molecular aberration the uncertainty level of the health technology assessment (HTA) by the pan Canadian Oncology Review (pCODR) was too high for consideration of funding or it was not submitted for consideration. Consequently, the goal of this study is to generate real world evidence to support HTA decision making throughout the life cycle of the product.",[406],[427,428,429,430],"targeted therapy","health technology assessment","real world evidence","quality of life",{"date":409,"type":37},{"date":433,"type":37},"2021-06-30",{"date":435,"type":22},"2028-05-01",{"name":43,"class":44},{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":23,"phases":446,"briefSummary":447,"conditions":448,"keywords":452,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":73},"100449420","monitoring-and-managing-glucose-levels-in-people-with-pancreatic-cancer-100449420","NCT05132244","Monitoring and Managing Glucose Levels in People With Pancreatic Cancer","Pancreatic Cancer Glucose Assessment and Regulation Study","PEGASUS","Inclusion Criteria:\n\n* Histological\u002Fcytological diagnosis of pancreatic ductal adenocarcinoma (PDAC).\n* Planned to undergo first-line systemic therapy with FOLFIRINOX.\n* Age greater than or equal to 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* Adequate bone marrow and organ function as defined by the following laboratory values:\n\n  1. Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10\\^9\u002FL.\n  2. Platelet count greater than or equal to 75 x 10\\^9\u002FL.\n  3. Hemoglobin greater than or equal to 9.0 g\u002FdL.\n  4. Estimated glomerular filtration rate (GFR) by Cockroft-Gault equation OR 24 hour urine collection greater than or equal to 40 ml\u002Fmin.\n  5. Creatinine clearance greater than or equal to 40 mL\u002Fmin using Cockcroft-Gault formula.\n  6. Potassium within normal limits, or corrected with supplements.\n  7. International normalized ratio (INR) less than or equal to 1.5.\n  8. Total serum bilirubin less than or equal to 2 x upper limit of normal (ULN) (any elevated bilirubin should be asymptomatic at enrollment) except for participants with documented Gilbert's syndrome who may only be included if the total bilirubin less than or equal to 3 x ULN or direct bilirubin less than or equal to 1.5 x ULN).\n  9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 x ULN (or less than or equal to 5 x ULN if liver metastases are present).\n* Able to understand and voluntarily sign the informed consent form.\n* Able to comply with the study visit schedule and other protocol requirements.\n* Able to swallow oral medications and has no contraindications to subcutaneous insulin injections.\n* Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 at baseline.\n* Life expectancy of more than 90 days as judged by the study doctor.\n\nExclusion Criteria:\n\n* Absence of distant or lymph node metastases. Participants with borderline resectable or locally advanced PDAC are not eligible.\n* Received prior systemic therapy (chemotherapy or any other anti-cancer agent) for treatment of metastatic PDAC. Participants who received adjuvant chemotherapy after surgical resection of early stage disease are eligible.\n* Currently receiving anti-cancer therapy (chemotherapy or any other anti-cancer agent).\n* Not fit for combination chemotherapy as judged by the study doctor.\n* Presence of brain metastases.\n* Known diagnosis of type I diabetes where strict glucose control and close Endocrinology follow-up is already indicated.\n* Known diagnosis of type II diabetes and already followed by Endocrinologist.\n* Female participants with a positive pregnancy test.\n* Participants who are not safe to include in the study as judged by the study doctor for any medical or non-medical reason.\n* Unable to comply with study assessments and follow-up.",{"count":352,"type":22},[25],"This study will investigate whether or not it is feasible to closely monitor and manage glucose levels in people with pancreatic cancer. It will also investigate what impact glucose management may have on pancreatic cancer.\n\nThis is a pilot study that will use continuous glucose monitors (CGM) to monitor glucose levels in approximately 50 participants with pancreatic cancer. Participants will receive standard chemotherapy with a combination of up to four drugs to treat their pancreatic cancer: oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin (FOLFIRINOX). To treat high glucose levels, participants will be randomly assigned to one of two groups: Group 1 will receive anti-hyperglycemic treatment as guided by an endocrinologist with the aim of maintaining glucose levels between 4 and 10 mmol\u002FL; Group 2 will receive anti-hyperglycemic treatment if their glucose levels are above 15 mmol\u002FL, which is standard care. Participants in both Groups 1 and 2 will receive standard anti-hyperglycemic treatments: metformin, insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, sodium glucose co-transporter (SGLT2) inhibitors, and dipeptidyl peptidase 4 (DPP-4) inhibitors.\n\nAfter 4 cycles of FOLFIRINOX, the CGM will be removed but any anti-hyperglycemic treatments will continue as needed. If participants discontinue treatment with FOLFIRINOX, they will continue to be followed for survival and subsequent anti-cancer therapy and will continue follow-up for glucose-related concerns at the discretion of their endocrinologist and\u002For medical oncologist.",[449,450,451],"Pancreatic Cancer","PDAC - Pancreatic Ductal Adenocarcinoma","Hyperglycemia",[453,454,455,456,457,458,459,460],"FOLFIRINOX","Continuous Glucose Monitor","Feasibility","Glycemic management","Endocrinologist","Intensive glucose intervention","Pilot","Glucose control","2025-09-17",{"date":407,"type":37},{"date":464,"type":37},"2024-04-16",{"date":466,"type":22},"2027-04",{"name":43,"class":44},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":23,"phases":477,"briefSummary":478,"conditions":479,"keywords":489,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":498,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":73},"100383469","phase-2-investigating-the-effects-of-atezolizumab-in-people-whose-tumour-dna-or-rna-indicates-possible-sensitivity-100383469","NCT04273061","Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity","Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention","CAPTIV-8","Inclusion Criteria:\n\n* Age greater than or equal to 18 years at the time of signature of informed consent.\n* Participants with an incurable solid tumour who have undergone whole genome and transcriptome analysis (WGTA) as part of Personalized OncoGenomics (POG) or equivalent program.\n\n  a. Participants must have had successful sequencing of their tumour, been formally reviewed by the POG (or POG-approved) genome analysts and found to have CAPTIV-8 factors identified (including Immune, Burden, Variant (IBV) score ≥ 5), been reviewed at the Molecular Tumour Board (MTB) (or site equivalent), and allocated to a specific tumour-defined cohort (that is open for enrolment) with a final opinion documented.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Participants must have measurable disease, as defined by RECIST 1.1.\n* Life expectancy of at least 12 weeks.\n* Adequate hematologic and end-organ function, as defined by the following laboratory results obtained within 28 days prior to the first study treatment:\n\n  1. Absolute neutrophil count (ANC) ≥ 1500 cells\u002FµL without granulocyte colony- stimulating factor support.\n  2. White blood cell (WBC) counts \\> 2500\u002FµL.\n  3. Lymphocyte count ≥ 500\u002FµL.\n  4. Serum albumin ≥ 2.5 g\u002FdL.\n  5. Platelet count ≥ 100,000\u002FµL without transfusion (without transfusion within 2 weeks of laboratory test used to determine eligibility).\n  6. Hemoglobin ≥ 9.0 g\u002FdL, participants may be transfused or receive erythropoietic treatment to meet this criterion.\n  7. International normalized ratio (INR) or activated partial thromboplastin time (aPTT) ≤ 1.5 × Upper Limit of Normal (ULN). This applies only to participants who are not receiving therapeutic anticoagulation; participants receiving therapeutic anticoagulation must have an INR or aPTT within therapeutic limits for at least 1 week prior to enrolment.\n  8. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 × ULN with the following exceptions: i) Participants with documented liver metastases: AST and\u002For ALT ≤ 5 × ULN. ii) Participants with documented liver or bone metastases: ALP ≤ 5 × ULN.\n  9. Serum bilirubin ≤ 1.5 × ULN. Participants with known Gilbert's syndrome who have serum bilirubin level ≤ 3 × ULN may be enrolled.\n  10. Serum creatinine ≤ 1.5 × ULN.\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than 1% (one percent) per year during the treatment period and for at least 5 months after the last dose of atezolizumab.\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse with a female partner of childbearing potential or who is pregnant) or use contraceptive measures that result in a failure rate of less than 1% (one percent) per year, and agreement to refrain from donating sperm, during the treatment period and for at least 5 months after the last dose of atezolizumab.\n* Asymptomatic participants with treated or untreated CNS lesions are eligible provided that all of the following criteria are met:\n\n  1. Measurable disease, per RECIST 1.1, must be present.\n  2. The participant has no history of intracranial hemorrhage or spinal cord hemorrhage.\n  3. The participant has not undergone stereotactic radiotherapy within 7 days prior to the initiation of study treatment, whole-brain radiotherapy within 14 days prior to initiation of study treatment, or neurosurgical resection within 28 days prior to initiation of study treatment.\n  4. The participant has no ongoing requirement for corticosteroids as therapy for CNS disease. Anticonvulsant therapy at a stable dose is permitted.\n* Ability to give informed consent for the study procedures defined in this protocol.\n\nExclusion Criteria:\n\n* Any prior treatment with monoclonal antibodies targeting the Programmed Death 1\u002FLigand (PD-1\u002FPD-L1) axis, including antibody-drug conjugates and other experimental agents.\n* Treatment with any approved or investigational agent or participation in another clinical trial with therapeutic intent within 14 days or five half-lives of the drug, whichever is longer, prior to enrollment. Participants receiving gonadotropin releasing hormone (GnRH) analogues may continue to receive treatment while participating in CAPTIV-8.\n* Pregnancy or breastfeeding.\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.\n* Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation.\n* Active autoimmune disease at any point within the last 2 years prior to enrollment including but not limited to:\n\n  1. Myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.\n  2. Participants with a history of autoimmune-related hypothyroidism on a stable dose of thyroid-replacement hormone may be eligible for this study.\n  3. Participants with controlled Type I diabetes mellitus on a stable dose of insulin regimen are eligible for this study.\n* Participants with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., participants with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\n\n  1. Rash must cover less than 10% (ten percent) of body surface area (BSA).\n  2. Disease is well controlled at baseline and only requiring low potency topical steroids.\n  3. No acute exacerbations of underlying condition within the last 12 months requiring treatment with either psoralen plus ultraviolet radiation (PUVA), methotrexate, retinoids, biologic agents, oral calcineurin inhibitors or high potency or oral steroids.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Positive test for HIV (participants with a history of\u002For symptoms of HIV are eligible only if serological tests are negative).\n* Participants with hepatitis B virus (HBV) are excluded if one of the following conditions is met:\n\n  1. Positive hepatitis B surface antigen (HBsAg) test at screening; or\n  2. Negative or positive hepatitis B surface antibody (HBsAb) test at screening accompanied by a positive total hepatitis B core antibody (HBcAb) test followed by a positive (per local laboratory definition) HBV DNA test.\n* Positive hepatitis C virus (HCV) antibody test followed by a positive HCV RNA test at screening.\n* Active tuberculosis.\n* Severe infections within 2 weeks prior to Cycle 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.\n* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina.\n* Major surgical procedure within 21 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study.\n* Prior allogeneic stem cell or solid organ transplant.\n* Treatment with systemic immunostimulatory agents (including but not limited to interferons, interleukin-2 (IL-2)) within 6 weeks or five half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1.\n* Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumour necrosis factor \\[anti-TNF\\] agents) within 2 weeks prior to Cycle 1, Day 1, or anticipated requirement for systemic immunosuppressive medications during the trial.\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab.\n* Participants who are otherwise felt by the treating clinician to be unfit to proceed with this protocol.",{"count":278,"type":22},[58],"This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and their cancer.\n\nThis is a Phase 2 study, which is undertaken after preliminary safety testing on a drug is completed, and will involve approximately 200 participants. Participants are assigned to one of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (GI), primary unknown, genitourinary (GU), sarcoma, gynecological, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks). In the first stage for each cohort, 8 participants will be enrolled and if no participants respond to treatment, enrollment to that cohort will be closed. If 1 or more participants respond to treatment, up to 16 additional participants will be enrolled to that cohort. Participants continue on treatment until they no longer may benefit from the treatment or they decide to stop treatment.",[480,481,482,483,484,485,486,487,488],"Breast Cancer","Lung Cancer","Gastrointestinal Cancer","Genitourinary Cancer","Gynecologic Cancer","Sarcoma","Unknown Primary Tumors","Head and Neck Cancer","Skin Cancer",[490,491,492,493,494,495,496,497],"Genomic analysis","Atezolizumab","Whole genome and transcriptome analysis","Immune Burden Variant score","Immune checkpoint inhibition","Personalized OncoGenomics","Phase 2","Precision targeting",{"date":407,"type":37},{"date":500,"type":37},"2020-06-17",{"date":502,"type":22},"2027-10",{"name":43,"class":44},{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":513,"conditions":514,"keywords":515,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":520,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":152},"100275786","prospectively-defining-metastatic-pancreatic-ductal-adenocarcinoma-subtypes-by-comprehensive-genomic-analysis-100275786","NCT02869802","Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis","PanGen","Inclusion Criteria:\n\n* Histological and\u002For radiological diagnosis of metastatic PDAC. Patients without a histological diagnosis of PDAC must undergo confirmatory tumour biopsy prior to treatment start date.\n* Planned for first-line systemic therapy with FOLFIRINOX or GP, either in routine care or in combination with an investigational agent(s) within a clinical trial.\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Adequate organ function\n* Life expectancy of \\> 90 days as judged by the investigator\n* Ability to give informed consent\n* Measurable disease by RECIST 1.1\n* Presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist. A minimum of 3 tumour cores must be safely obtainable under CT or US guidance.\n* Fit enough to safely undergo a tumour biopsy as judged by the investigator\n* Ability to lie supine for \\> 60 minutes\n\nPatients in the archival cohort must also fulfil the following criteria:\n\n* Archival tumour sample available (either a previous tumour diagnostic biopsy or resection specimen)\n\nExclusion Criteria:\n\n* Absence of distant or lymph node metastases. Patients with borderline resectable or locally advanced PDAC are not eligible.\n* Received prior systemic therapy (chemotherapy or any other anti-cancer agent) in the advanced setting. Patients who received adjuvant chemotherapy after surgical resection of early stage disease are eligible.\n* Currently receiving anti-cancer therapy (chemotherapy or any other anti-cancer agent)\n* Not fit for combination chemotherapy as judged by the investigator\n* Presence of brain metastases\n* Female patients with positive pregnancy test\n* Patients who are not safe to include in the study as judged by the investigator for any medical or non-medical reason\n* Unable to comply with study assessments and follow-up",{"count":512,"type":22},190,"Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.",[406,449],[406,449,516,517,518,519],"Advanced Pancreatic Ductal Adenocarcinoma","PDAC","Genomic Analysis","Molecular subtyping",{"date":407,"type":37},{"date":522,"type":37},"2016-10-06",{"date":524,"type":22},"2027-12",{"name":43,"class":44},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":533,"enrollmentInfo":534,"targetDuration":4,"studyType":23,"phases":536,"briefSummary":537,"conditions":538,"keywords":542,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":45},"100221093","personalized-oncogenomics-pog-program-of-british-columbia-100221093","NCT02155621","Personalized Oncogenomics (POG) Program of British Columbia","Personalized OncoGenomics (POG) Program of British Columbia: Connecting Cancer Genomics to Cancer Care","Inclusion criteria:\n\n1. Patients must agree to allow their archival specimens to be used and possibly completely depleted for these analyses.\n2. Willing and able to have a study-specific biopsy or resection of the tumour or metastatic site OR if there is adequate archival material available, either fresh frozen or FFPE (if specimen is thought to be adequate) that is taken after the most recent chemo or radiation. Ideally this sample should have been collected within 16 weeks of the date of consent. If archival tissue is not adequate and if a biopsy is not feasible or deemed medically safe by the investigators the patient would become ineligible.\n3. Patients must understand and agree to provide a blood test (or other sample of normal DNA) for germline genomic analysis.\n4. ECOG PS 0 or 1.\n5. Age \\>\u002F= 18 years.\n6. Estimated life expectancy \\>\u002F= 6 months and high likelihood of being clinically fit for a therapeutic clinical trial in 3-6 months.\n7. Measurable disease with RECIST v1.1 (or updated version).\n8. Adequate organ function.\n9. Patients must clearly understand that this data may be used to help guide treatment recommendations, including the avoidance of some therapeutic agents or the suggestion to use standard cytotoxic chemotherapy agents.\n10. Willingness to have their de-identified genomic and clinical data shared with national and international research collaborators and data sharing platforms (as detailed in the consent form).\n11. Willingness to be contacted for future studies based on the data that is generated by participation in POG; included in this is the anticipation that patient would be fit or a candidate for clinical trials.\n\nExclusion criteria:\n\n1. Unable or unwilling to consent to the above tissue and blood requirements.\n2. Significant medical condition that in the opinion of the treating or consenting oncologist and\u002For the POG central office review team renders the subject not suitable for participation. This includes the likelihood that a subject would be suitable for a clinical trial within 12 weeks after POG biopsy.\n3. Unwilling or unable to provide treatment and outcome follow up information to the BC Cancer or affiliated investigators.\n4. Unwilling to receive medically actionable findings (germline and\u002For somatic).","85 Years",{"count":535,"type":22},5000,[25],"The genomic heterogeneity of cancers implies that to effectively use targeted therapies the investigators will need to assess each individual cancer and match it to a biologically relevant targeted therapy. The investigators will use full genome sequencing to try to identify cancer \"drivers\" and corresponding drugs that may inhibit these pathways.",[539,540,541],"Metastatic Cancers","Advanced Cancers","Cancers That Cannot be Treated With Curative Intent",[543,544,545,546],"cancer genomics","precision medicine","metastatic cancer","clinical decision-making",{"date":407,"type":37},{"date":549,"type":4},"2014-07",{"date":551,"type":22},"2026-03",{"name":43,"class":44},{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":23,"phases":561,"briefSummary":562,"conditions":563,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":45},"100567207","phase-2-genomic-and-transcriptomic-predictors-of-sequential-sg-sensitivity-after-t-dxd-in-erher2-low-metastatic-breast-cancer-100567207","NCT06665178","Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+\u002FHER2-Low Metastatic Breast Cancer","Whole Genome and Transcriptome Tumor Sequencing to Identify Predictors of Sensitivity to Sequential Sacituzumab Govitecan (SG) Following Trastuzumab Deruxtecan (T-DXd) Treatment in ER+\u002FHER-2 Low Metastatic Breast Cancer","Inclusion Criteria\n\nPatients must meet all of the following inclusion criteria to be eligible for participation in this study:\n\n1. Willing and able to provide signed informed consent approved by UBC\u002FBC Cancer REB\n2. Female or male patients, regardless of race and ethnic group, who are ≥18 years old at the time of informed consent\n3. Patients with locally advanced or metastatic ER+\u002FHER2 low (defined as IHC 1+ or 2+ but FISH or CISH negative by ratio as per ASCO\u002FCAP guidelines) breast cancer. Patients with imaging confirmed inoperable locally advanced breast cancer for which treatment is palliative in intent are also permitted.\n4. Prior treatment must have included prior endocrine based treatment in the metastatic setting in conjunction with a CDK4\u002F6 inhibitor.\n5. Prior treatment must include at least 1 line of chemotherapy which must include trastuzumab deruxtecan (T-DXd) as the immediate prior line of therapy prior to study enrollment\n6. The tumour must be accessible to be able to safely perform image guided biopsies for WGS and WTS.\n7. Negative serum pregnancy test at baseline for pre-menopausal patients (within 14 days prior to randomization) and agreement to use medically approved precautions to prevent pregnancy during the study and for 12 weeks following the last dose of SG\n8. Patients can have measurable or non measurable (but assessable) disease by CT or MRI as per RECIST Version 1.1 criteria as evaluated locally. Tumor lesions situated in a previously irradiated area are considered measurable if unequivocal progression has been documented in such lesions since radiation.\n9. ECOG PS 0-2\n10. Life expectancy ≥ 3 months\n11. Acceptable bone marrow and organ function defined by the following laboratory values:\n\n    1. Absolute neutrophil count ≥1.0 x 109\u002FL\n    2. Platelets ≥100 x 109\u002FL\n    3. Hemoglobin ≥9.0 g\u002FdL\n    4. INR ≤1.5\n    5. Serum creatinine clearance \\>50 mL\u002Fmin\n    6. In absence of liver metastases, direct bilirubin ≤1.5 x ULN, ALT and AST should be below ≤2.5 x ULN. If the patient has liver metastases, ALT and AST should be \\< 5.0 x ULN.\n12. Controlled brain metastasis (as per clinical determination) is allowed in the study at least 4 weeks before treatment. (Controlled brain metastasis is defined as no longer symptomatic from brain metastasis or no longer requiring higher doses of corticosteroids (\\> 10 mg Dexamethasone per day) for CNS management. Anticonvulsants and stable corticosteroids dose can be included in the study).\n\nExclusion Criteria\n\nPatients who meet any of the following exclusion criteria are not eligible to be enrolled in this study:\n\n1. Patient is currently participating in any other type of medical research judged not to be scientifically or medically compatible with this study.\n2. Patient has a known hypersensitivity to SG, irinotecan or its active metabolite SN-38.\n3. Patients not available for follow up\n4. Patients who are not willing to consider systemic treatment options\n5. Tumor not accessible or not safe to perform biopsies\n6. Patient has not had resolution of all acute toxic effects of prior anti-cancer therapy to CTCAE v. 5.0 grade ≤1 (except toxicities not considered a safety risk for the patient at investigators discretion: e.g. grade 2 peripheral neuropathy from prior chemotherapy that is stable).\n7. Have an active second malignancy. Patients with a history of malignancy that has been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or patients with surgically cured tumors with low risk of recurrence (e.g. non-melanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar) are allowed to enroll.\n8. Have known active central nervous system (CNS) metastases. Patients with previously treated brain metastases may participate provided they have stable CNS disease (defined as no longer symptomatic from brain metastasis or no longer requires higher doses of corticosteroids (\\> 10 mg Dexamethasone per day) for CNS symptom management. Anticonvulsants and stable corticosteroids dose can be included in the study). Screening for brain metastasis not required for enrollment.\n9. Pregnancy and breast feeding\n10. Patient without an adequate hematologic, renal and hepatic function as per above inclusion criteria\n11. Patient has a pre-existing condition with uncontrolled diarrhea, chronic inflammatory bowel disease or GI perforation within 6 months prior to enrollment.\n12. Have active serious infection requiring antibiotics.",{"count":329,"type":22},[58],"Advanced hormone positive (HR+), HER2 negative breast cancer continues to pose a challenge when patients have progressed on CDK4\u002F6 inhibitor and endocrine therapy leaving limited treatment options. Antibody-drug conjugates (ADCs) such as sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) have changed practice due to significant improvement in progression free survival (PFS) and overall survival (OS) seen in this disease setting. There is a genuine interest to use SG sequentially after T-DXd, however there is no current prospectively curated evidence to support this strategy. Though the epitope is different, the payload are both topoisomerase I inhibitors. Thus, evidence is needed of both clinical efficacy and identification of mechanisms of sensitivity and resistance to sequential ADCs in HER-2 low MBC.\n\nIt is hypothesized that performing whole genome and whole transcriptome sequencing in fresh tumour biopsies post progression of T-DXd and prior to SG in ER+\u002FHER2 low metastatic breast cancer (MBC) will provide mechanistic insights into identifying biomarkers, and thus patients, sensitive to sequential SG.",[480],"2025-06-19",{"date":566,"type":37},"2025-06-25",{"date":568,"type":37},"2025-03-31",{"date":570,"type":22},"2028-12-01",{"name":43,"class":44},{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":4,"eligibilityCriteria":578,"healthyVolunteers":579,"sex":105,"minAge":54,"maxAge":533,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":582,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":45},"100582362","phase-2-time-restricted-eating-in-haematological-malignancies-100582362","NCT06862323","Time Restricted Eating in Haematological Malignancies","Does Timing Matter? A Trial of Time Restricted Eating in Haematological Malignancies","Inclusion Criteria:\n\nExperimental Participants:\n\n* Diagnosis of CLL or SLL, Age 18-85\n* Peripheral blood lymphocytes \\>20 x 10\\^9\u002FL\n* Hemoglobin \\>90g\u002FL\n* Platelets ˃90 x 10\\^9\u002FL\n* BMI of \\>=20kg\u002Fm2\n* ECOG Performance Status \\>=2\n* Not following any form of IF for 4 months prior to study\n\nControl Participants:\n\n* Absence of cancer diagnosis (active or historical)\n* Age 18-85, Peripheral blood lymphocytes \\\u003C5 x10\\^9\u002FL\n* BMI of \\>=20kg\u002Fm2\n* ECOG Performance Status \\>=2\n* Not following any form of IF for 4 months prior to study\n\nExclusion Criteria:\n\nExperimental and Control Participants:\n\n* Unable to give consent\n* On medications required to be taken with food during the fasting window\n* Pregnant or breastfeeding\n* Diabetes mellitus\n* BMI drop to \\\u003C 18.5kg\u002Fm2 at any time during study\n* Anti-lymphoma therapy within the past 3 months\n* Expected to initiate anti-lymphoma therapy within the next 3 months\n* Unable to fast due to a digestive system disorder\n* \\> 85 years of age (due to frailty, increased risk of infection, and burden of additional blood collections)",true,{"count":581,"type":22},75,[58],"The goal of this clinical trial is to learn if time restricted eating (TRE), a form of intermittent fasting, can impact health outcomes in patients with chronic lymphocytic leukemia (CLL). The main questions it aims to answer are:\n\n* In patients with CLL, is there a decrease or stabilization in cancer cell counts associated with TRE compared to baseline?\n* Is there a decrease in immune cell autophagy (a cellular recycling process) activity associated with TRE compared to baseline?\n* Does adherence to a TRE regimen improve patient experience and quality of life?\n\nImmune cell autophagy activity in cancer patients will be compared to a subset of control participants without cancer.\n\nParticipants will:\n\n* Adhere to a 16\u002F8 fasting regimen, which involves eating as normal for 8 hours per day and fasting (only consuming water, black coffee or black tea) for the remaining 16 hours. They will follow this intervention for their choice of either 3 or 6 months.\n* Complete monthly blood collections\n* Complete weekly journal entries to record weekly weight and timing of first and last daily meals\n* Complete weekly safety check-ins with a study team member for the first 4 weeks of the study and then bi-weekly thereafter\n* Complete 3 quality of life questionnaires\n* Provide 3 stool samples (optional component of study)\n* Complete an end of study interview (optional component of study)",[406,585],"Chronic Lymphocytic Leukemia",[587,588,589,406,585,590,591,592,593],"Time Restricted Eating","Intermittent Fasting","Diet","Autophagy","Microbiome","Inflammation","Epigenetics","2025-06-11",{"date":596,"type":37},"2025-06-13",{"date":598,"type":22},"2025-06",{"date":600,"type":22},"2027-08",{"name":43,"class":44},{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":608,"eligibilityCriteria":609,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":4,"enrollmentInfo":610,"targetDuration":4,"studyType":23,"phases":612,"briefSummary":613,"conditions":614,"keywords":615,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":45},"100588122","sabr-primer---evaluating-stereotactic-ablative-radiotherapy-for-primary-and-regional-breast-tumors-100588122","NCT06937281","SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors","A Phase II Trial Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors (SABR-PRIMeR)","SABR PRIMER","Inclusion Criteria:\n\n1. Pathologically confirmed AJCC 7th\u002F8th edition Stage IV invasive ductal carcinoma or invasive lobular carcinoma of the breast.\n2. Measurable disease in the breast, suitable to receive radiotherapy.\n3. Receiving or planned to receive systemic therapy.\n\n   a. The following should be held for the duration of treatment: cytotoxic chemotherapy, CDK4\u002F6 inhibitors, T-DXd\n4. Patients are allowed to have SABR for oligometastatic disease as clinically indicated\n5. Age 18 or older\n6. ECOG Performance Status 0-2\n7. Life expectancy greater than 6 months\n8. Able and willing to provide informed consent\n9. Able to complete patient reported outcome questionnaires\n\nExclusion Criteria:\n\n1. Contraindications to radiotherapy, including a history of SLE, systemic scleroderma, IPF, ataxia telangiectasia, pregnancy\n2. Previous history of locoregional radiotherapy to the ipsilateral breast",{"count":611,"type":22},40,[25],"The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer.\n\nSecondary objectives will be overall survival, progression-free survival and time to switch of next line of systemic therapy.\n\nRadiation-related adverse events will be assess, with a specific focus on dermatitis, lymphedema and brachial plexopathy.\n\nThe exploratory objective is to correlate toxicities and outcomes with peripheral blood biomarkers and circulating tumor DNA to potentially help predict responses in future patients receiving combined therapy.",[480,333],[65],"2025-04-22",{"date":618,"type":37},"2025-04-24",{"date":620,"type":22},"2025-07-01",{"date":622,"type":22},"2030-07-30",{"name":43,"class":44},{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":23,"phases":633,"briefSummary":634,"conditions":635,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":639,"completionDateStruct":640,"leadSponsor":641,"locationsCount":45},"100588121","dotatate-pet-for-meningioma-radiation-planning-100588121","NCT06937268","DOTATATE PET for Meningioma Radiation Planning","Exploratory Analysis of DOTATATE PET for Meningioma Radiation Planning","DOTATATE-RT","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Able and willing to comply with the study procedures\n* Intact meningioma requiring definitive radiation\n* Post-operative meningioma requiring adjuvant radiation\n* No prior radiation therapy or medical therapy directed at the tumour\n\nExclusion Criteria:\n\n* Breastfeeding or pregnancy\n* Claustrophobia or inability to lie still in a supine position\n* Unwillingness or inability to provide informed consent",{"count":383,"type":22},[25],"68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET",[636],"Meningioma","2025-04-15",{"date":616,"type":37},{"date":598,"type":22},{"date":373,"type":22},{"name":43,"class":44},{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":648,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":105,"minAge":54,"maxAge":650,"enrollmentInfo":651,"targetDuration":4,"studyType":23,"phases":652,"briefSummary":653,"conditions":654,"keywords":656,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":661,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":667,"locationsCount":668},"100443172","phase-2-rapid-simple-targeted-radiation-treatment-for-brain-metastases-100443172","NCT05050929","RAPid SimPLE Targeted Radiation Treatment for Brain Metastases","Randomized Phase II Non-Inferiority Study of 5-Day Versus 1-Day RAPid SimPLE (RAPPLE) Targeted Radiation Treatment for Brain Metastases","RAPPLE","Inclusion Criteria:\n\nSubjects must meet all of the following criteria to be eligible for participation in this study:\n\n* Age ≥ 18\n* Pathological diagnosis of a non-hematopoietic malignancy\n* Brain metastases of any size\n* Any number of untreated or progressing, previously treated brain metastases that can all be contoured and targeted\n* Presence of extracranial disease\n* Diagnosis-Specific Graded Prognostic Assessment ≤ 2.0. (https:\u002F\u002Fbrainmetgpa.com\u002F) or Graded Prognostic Assessment ≤ 2.0 (Appendix I)\n* Able to complete the EuroQOL (EQ-5D-5L) questionnaire\n* Willing and able to have regular imaging follow up\n* Feasible to start protocol treatment within 14 days of participant enrolment\n* Karnofsky Performance Score (KPS) ≥ 50\n\nExclusion Criteria:\n\nSubjects are excluded from the study if any of the following criteria apply:\n\n* Inability to have a brain MRI\n* WBRT less than 3 months prior to randomization\n* Disseminated leptomeningeal carcinomatosis (limited pachymeningeal disease is permitted)\n* Multiple sclerosis\n* Neurologically declining despite corticosteroids\n* Appropriate for surgery or stereotactic radiosurgery\n* Germ cell and primary brain tumours\n* Systemic lupus erythematosis, scleroderma, or other connective tissue disorders not in remission\n* Any other serious intercurrent illness or medical condition judged by the local investigator to compromise the participant's safety, preclude safe administration of the planned protocol treatment, or prevent the participant from being managed according to the protocol guidelines\n* Pregnancy\n* Potentially fertile men or women of childbearing potential who are unwilling to employ highly effective contraception","100 Years",{"count":56,"type":22},[58],"The aim of the study is to show that rapid, simple targeted radiotherapy to brain metastases with 8 Gy \u002F 1 is non-inferior to 20 Gy \u002F 5 in terms of overall survival for patients with poor prognosis.",[655],"Brain Metastases, Adult",[141,657,658,659,660],"randomized clinical trial","phase II","non-inferiority","overall survival",{"date":662,"type":37},"2025-04-17",{"date":664,"type":37},"2022-07-01",{"date":666,"type":22},"2027-12-30",{"name":43,"class":44},6,""]